Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 6/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385974 | 0.88 | RAB9A (0.64) | TSHRHPGDMAPK1CA12CA1 | |
| SCHEMBL1348058 | 0.88 | RAB9A (0.64) | TSHRHPGDMAPK1CA12CA1 | |
| SCHEMBL1346856 | 0.82 | FLT1 (0.55) | TSHRHPGDMAPK1CA12CA1 | |
| SCHEMBL1346964 | 0.79 | FLT1 (0.58) | GSK3BRAB9AKDM4ENPC1MAPT | |
| SCHEMBL27837901 | 0.79 | GSK3B (0.78) | MAPK1GSK3BTDP1RAB9AKDM4E | |
| SCHEMBL12133365 | 0.78 | GSK3B (0.50) | CA12CA1CA2CA9GSK3B | |
| SCHEMBL13262011 | 0.76 | GSK3B (0.58) | CA12CA1CA2CA9GSK3B | |
| SCHEMBL1346484 | 0.75 | GSK3B (0.50) | CA12CA1CA2CA9GSK3B | |
| SCHEMBL1346482 | 0.74 | KDR (0.58) | GSK3BRAB9AKDM4ENPC1MAPT | |
| SCHEMBL13604111 | 0.74 | KDR (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103224493-A | Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO LTD | 2013-07-31 | — | — | CN | disclosed |
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063034-B2 | Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| CN-101600712-A | Novel oxadiazole derivative and thiadiazole derivative having angiogenesis inhibitory activity | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-12-09 | — | — | CN | disclosed |
| EP-2128156-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-2128156-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016354-A1 | NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY | FLT4, VEGFA, FLT1 | TSHR 514/4885HPGD 474/4885MAPK1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.